SIGA sinks on PharmAthene win in smallpox drug dispute
This article was originally published in Scrip
Executive Summary
Shares of SIGA Technologies plummeted as low as 43.2%, or $2.04, on 22 September after a court ruled that the firm must evenly split any profits it gains from the sale of its investigational smallpox antiviral drug ST-246 with PharmAthene, whose shares gained as much as 28.3%, or 64 cents.